Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Telik |
---|---|
Information provided by: | Telik |
ClinicalTrials.gov Identifier: | NCT00047801 |
The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every three weeks in combination with docetaxel (Taxotere) in the treatment of patients with non-small cell lung cancer that is resistant to platinum-based chemotherapy.
Condition | Intervention | Phase |
---|---|---|
Carcinoma, Non-Small-Cell Lung |
Drug: TLK286 in combination with docetaxel |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel (Taxotere) in Platinum-Resistant Non-Small Cell Lung Cancer |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria include:
Exclusion criteria include:
United States, California | |
Cancer Institute Medical Group | |
Los Angeles, California, United States, 90025 | |
UCLA Medical Center | |
Los Angeles, California, United States, 90095 | |
United States, Indiana | |
Indiana University Cancer Center | |
Indianapolis, Indiana, United States, 46202 | |
United States, Texas | |
M.D. Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Study ID Numbers: | TLK286.2012 |
Study First Received: | October 18, 2002 |
Last Updated: | January 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00047801 |
Health Authority: | United States: Food and Drug Administration |
Docetaxel Thoracic Neoplasms Non-small cell lung cancer Respiratory Tract Diseases Lung Neoplasms |
Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type |
Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |